2 completed, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow Erysipelas: new trials by email Literature Review of Erysipelas trials Research Report on Erysipelas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections Daptomycin, Brilacidin - Skin Infection, Bacterial Infection | Phase 2 | Completed | Cellceutix Corporation | 215 | 2014-02-01 | 2018-09-26 |
| A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study TR701 FA - Major Cutaneous Abscess, Cellulitis | Phase 2 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 200 | 2012-02-15 | 2018-08-29 |
| The Use of Oral Steroids in the Treatment of Cellulitis Prednisone, Placebo Oral Tablet - Cellulitis, Erysipelas | Phase 2 | Withdrawn | Milton S. Hershey Medical Center | 2010-01-15 | 2017-07-25 |
Cellulitis (3) · Abscess (1) · Bacterial Infections (1) · Staphylococcal Infections (1) · Wound Infection (1)
Bacterial Infections and Mycoses (3) · Connective Tissue Diseases (3) · Gram-Positive Bacterial Infections (3) · Infections (3) · Inflammation (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Skin Diseases (3) · Skin Diseases, Bacterial (3) · Skin Diseases, Infectious (3) · Skin and Connective Tissue Diseases (3) · Streptococcal Infections (3) · Suppuration (3) · Bacterial Infections (2)
Daptomycin (1) · Prednisone (1) · brilacidin (1) · tedizolid (1)
Cellceutix Corporation (1) · Milton S. Hershey Medical Center (1) · Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
United States (2)
Philippe Prokocimer, MD (1) · Scott Goldstein, DO (1) · William O'Riordan, MD (1)